Amicus (FOLD) Receives a Buy from Cowen & Co.

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Amicus (FOLD), with a price target of $31. The company’s shares opened today at $12.28.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 22.4% and a 47.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Currently, the analyst consensus on Amicus is a Strong Buy with an average price target of $22.67, which is an 84.6% upside from current levels. In a report issued on August 1, H.C. Wainwright also maintained a Buy rating on the stock with a $18 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.70 and a one-year low of $8.27. Currently, Amicus has an average volume of 3.1M.

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FOLD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease.